{"id":13731,"date":"2025-10-22T21:31:41","date_gmt":"2025-10-22T19:31:41","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=13731"},"modified":"2025-12-11T17:57:21","modified_gmt":"2025-12-11T15:57:21","slug":"risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/","title":{"rendered":"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone)"},"content":{"rendered":"\n<p><em>Kliinilise keemia ja laboratoorse hematoloogia osakond<\/em><\/p>\n\n\n\n<p><strong>Risperidoon <\/strong>on at\u00fc\u00fcpiliste antips\u00fchhootikumide r\u00fchma kuuluv preparaat, mis on n\u00e4idustatud skisofreenia ja bipolaarse h\u00e4irega seotud maania-episoodide raviks lastel ja t\u00e4iskasvanutel. Samuti kasutatakse risperidooni l\u00fchiajaliseks agressiivsuse raviks Alzheimer\u2019i t\u00f5vega patsientidel ning keskmisest madalama intellektiga v\u00f5i vaimse puudega \u00fcle 5-aastastel lastel.<\/p>\n\n\n\n<p>Risperidooni manustatakse suukaudselt ning see imendub t\u00e4ielikult. Maksimaalne plasmakontsentratsioon saavutatakse 1\u20132 tunniga. Risperidooni metabolism toimub maksas, kus kahe ens\u00fc\u00fcmi vahendusel tekib sarnase farmakoloogilise aktiivsusega 9-h\u00fcdroks\u00fcrisperidoon. Risperidoon koos 9-h\u00fcdroks\u00fcrisperidooniga moodustavad ravimi aktiivse fraktsiooni.<\/p>\n\n\n\n<p>Risperidooni tasakaalukontsentratsioon plasmas saavutatakse enamikel patsientidel \u00fche p\u00e4evaga, 9-h\u00fcdroks\u00fcrisperidooni 4\u20135 p\u00e4evaga. Plasmas seondub risperidoon albumiiniga ja alfa1-gl\u00fckoproteiiniga. \u00dche n\u00e4dala jooksul p\u00e4rast manustamist eritub 70% ravimist uriiniga ja 14% v\u00e4ljaheitega. Risperidooni poolv\u00e4\u00e4rtusaeg on 3 tundi, 9-h\u00fcdroks\u00fcrisperidoonil 24 tundi. Neeru- v\u00f5i maksakahjustustega patsientidel on vajalik annuse kohandamine.<\/p>\n\n\n\n<p>K\u00f5ige sagedamini esinevateks k\u00f5rvaltoimeteks on parkinsonism, sedatsioon\/unisus, peavalu ja unetus. \u00dcleannustamisel v\u00f5ivad tekkida unisus, sedatsioon, tahh\u00fckardia, h\u00fcpotensioon ning ekstrap\u00fcramidaalsed s\u00fcmptomid, harvem QT-intervalli pikenemine ja krambid.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n<p>Proov tuleb v\u00f5tta vahetult enne j\u00e4rgmise ravimiannuse manustamist!<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"15%\"><strong>Katsuti<\/strong><\/td><td width=\"84%\">K2E\/K3E-katsuti (lilla kork)<\/td><\/tr><tr><td><\/td><td><strong>S\u00e4ilivus<\/strong><\/td><td>Plasmas +4 \u00b0C \u00fcks n\u00e4dal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsi tegemise aeg<\/strong><strong>:<\/strong> \u00fcks kord n\u00e4dalas<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsimeetod<\/strong><strong>:<\/strong> vedelikkromatograafia-massispektromeetria (LC-MS\/MS)<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Referentsv\u00e4\u00e4rtused<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"69%\"><strong>Soovituslik terapeutiline vahemik (risperidoon + 9-h\u00fcdroks\u00fcrisperidoon)*<\/strong><\/td><td width=\"30%\">20\u201360 \u00b5g\/L<\/td><\/tr><tr><td><\/td><td><strong>Toksiline kontsentratsioon*<\/strong><\/td><td>&gt;120 \u00b5g\/L<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*C. Hiemke et al (2018). \u201eConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017\u201c Pharmacopsychiatry 2018; 51: 9\u201362<\/p>\n\n\n\n<p>Antud vahemik p\u00f5hineb populatsiooniuuringutel, seega ei pruugi olla rakendatav igale patsiendile. M\u00f5ne patsiendi puhul v\u00f5ib optimaalne ravivastus olla ravimikontsentratsiooni juures, mis j\u00e4\u00e4b antud vahemikust v\u00e4lja.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n<p>Ravi j\u00e4lgimine, optimaalse raviskeemi leidmine ja kontroll, ravimim\u00fcrgistuse diagnostika.<\/p>\n\n\n\n<p>Koostajad: Julia Keller, Jelena Beljantseva<br>03.06.2020<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kliinilise keemia ja laboratoorse hematoloogia osakond Risperidoon on at\u00fc\u00fcpiliste antips\u00fchhootikumide r\u00fchma kuuluv preparaat, mis on n\u00e4idustatud skisofreenia ja bipolaarse h\u00e4irega seotud maania-episoodide raviks lastel ja t\u00e4iskasvanutel. Samuti kasutatakse risperidooni l\u00fchiajaliseks agressiivsuse raviks Alzheimer\u2019i t\u00f5vega patsientidel ning keskmisest madalama intellektiga v\u00f5i vaimse puudega \u00fcle 5-aastastel lastel. Risperidooni manustatakse suukaudselt ning see imendub t\u00e4ielikult. Maksimaalne plasmakontsentratsioon saavutatakse [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7301,"menu_order":31,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-13731","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Kliinilise keemia ja laboratoorse hematoloogia osakond Risperidoon on at\u00fc\u00fcpiliste antips\u00fchhootikumide r\u00fchma kuuluv preparaat, mis on n\u00e4idustatud skisofreenia ja bipolaarse h\u00e4irega seotud maania-episoodide raviks lastel ja t\u00e4iskasvanutel. Samuti kasutatakse risperidooni l\u00fchiajaliseks agressiivsuse raviks Alzheimer\u2019i t\u00f5vega patsientidel ning keskmisest madalama intellektiga v\u00f5i vaimse puudega \u00fcle 5-aastastel lastel. Risperidooni manustatakse suukaudselt ning see imendub t\u00e4ielikult. Maksimaalne plasmakontsentratsioon saavutatakse [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T15:57:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\\\/\",\"name\":\"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-10-22T19:31:41+00:00\",\"dateModified\":\"2025-12-11T15:57:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ravimiseire uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/","og_locale":"et_EE","og_type":"article","og_title":"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor","og_description":"Kliinilise keemia ja laboratoorse hematoloogia osakond Risperidoon on at\u00fc\u00fcpiliste antips\u00fchhootikumide r\u00fchma kuuluv preparaat, mis on n\u00e4idustatud skisofreenia ja bipolaarse h\u00e4irega seotud maania-episoodide raviks lastel ja t\u00e4iskasvanutel. Samuti kasutatakse risperidooni l\u00fchiajaliseks agressiivsuse raviks Alzheimer\u2019i t\u00f5vega patsientidel ning keskmisest madalama intellektiga v\u00f5i vaimse puudega \u00fcle 5-aastastel lastel. Risperidooni manustatakse suukaudselt ning see imendub t\u00e4ielikult. Maksimaalne plasmakontsentratsioon saavutatakse [&hellip;]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-12-11T15:57:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/","name":"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-10-22T19:31:41+00:00","dateModified":"2025-12-11T15:57:21+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/risperidoon-ja-9-hudroksurisperidoon-p-risperidone9-hydroxyrisperidone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Ravimiseire uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/"},{"@type":"ListItem","position":4,"name":"Risperidoon ja 9-h\u00fcdroks\u00fcrisperidoon (P-risperidone+9-hydroxyrisperidone)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Kliinilise keemia ja laboratoorse hematoloogia osakond Risperidoon on at\u00fc\u00fcpiliste antips\u00fchhootikumide r\u00fchma kuuluv preparaat, mis on n\u00e4idustatud skisofreenia ja bipolaarse h\u00e4irega seotud maania-episoodide raviks lastel ja t\u00e4iskasvanutel. Samuti kasutatakse risperidooni l\u00fchiajaliseks agressiivsuse raviks Alzheimer\u2019i t\u00f5vega patsientidel ning keskmisest madalama intellektiga v\u00f5i vaimse puudega \u00fcle 5-aastastel lastel. Risperidooni manustatakse suukaudselt ning see imendub t\u00e4ielikult. Maksimaalne plasmakontsentratsioon saavutatakse&hellip;","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=13731"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13731\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7301"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=13731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}